retatrutide ada 2025 results Lindsay Maggio, MD, MPH | 📣 News you need to know — is almost here, and the data is remarkable. Eli Lilly just released Phase 3 for retatrutide, Retatrutide, a new weight loss

"Analysis of common mutations in the galactose-1-phosphate uridyl transferase gene: new assays to increase the sensitivity and specificity of newborn screening for galactosemia"

[DOI] [PMC free article] [PubMed] [Google Scholar] 114.Ushida Y.S.H., Yanaka A

European Journal of Inflammation

Recognizing glucose metabolism reprogramming as a pivotal therapeutic target in oncology, we emphasize the indispensable role of nanomedicine in overcoming persistent barriers to advance tumor-selective metabolic intervention, thereby elevating treatment efficacy and accelerating the clinical translation of precision nanotherapeutics